Last quarter (Q3 2023), Spero Therapeutics's total revenue was $25.47M, an increase of 2254.25% from the same quarter last year. In Q3, Spero Therapeutics's net income was $-3.19M. See Spero Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 76.61M	$ 53.51M	$ 18.26M	$ 9.33M	$ 18.15M	$ 3.97M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 77.70M	$ 53.51M	$ 18.26M	-	-	-
Operating Expense	$ 37.79M	$ 95.71M	$ 106.23M	$ 88.44M	$ 81.36M	$ 46.77M
Operating Income	$ -3.19M	$ -42.20M	$ -87.97M	$ -79.11M	$ -63.22M	$ -42.81M
Net Non Operating Interest Income Expense	$ 3.64M	$ 1.11M	$ -1.59M	$ 401.00K	$ 1.33M	$ 1.10M
Other Income Expense	$ -88.00K	$ 5.32M	$ 191.00K	$ 432.00K	$ 963.00K	$ 43.00K
Pretax Income	$ 597.00K	$ -46.41M	$ -89.76M	$ -78.28M	$ -60.92M	$ -41.66M
Tax Provision	$ 2.20M	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -1.60M	$ -46.41M	$ -89.76M	$ -78.28M	$ -60.92M	$ -41.66M
Basic EPS	$ -0.57	$ -1.23	$ -2.91	$ -3.52	$ -3.35	$ -2.60
Diluted EPS	$ 0.44	$ -1.23	$ -2.91	$ -3.52	$ -3.35	$ -2.60
Basic Average Shares	$ 195.39M	$ 37.59M	$ 30.90M	$ 22.39M	$ 18.16M	$ 16.00M
Diluted Average Shares	$ 195.39M	$ 37.59M	$ 30.90M	$ 22.39M	$ 18.16M	$ 16.00M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 37.79M	$ 95.71M	$ 106.23M	$ 88.44M	$ 81.36M	$ 46.77M
Net Income From Continuing And Discontinued Operation	$ -1.61M	$ -46.41M	$ -89.76M	$ -78.28M	$ -60.92M	$ -41.66M
Normalized Income	$ -4.89M	$ -15.80M	-	$ -78.28M	$ -61.15M	$ -41.66M
Interest Expense	-	-	-	$ 0.00	-	-
EBIT	$ -1.11M	$ -46.41M	$ -88.16M	$ -78.28M	$ -63.22M	$ -42.81M
EBITDA	$ -649.00K	$ -45.53M	$ -87.27M	$ -77.52M	$ -62.47M	$ -42.40M

Currency in USD

Spero Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing